In addition to the genes listed above, Myriad Genetics MyRisk® Hereditary Cancer Test includes RiskScore®, a precision medicine tool that predicts a woman’s five year and lifetime risk for developing breast cancer. RiskScore analyzes over 100 genetic markers combined with the Tyrer-Cuzick model to estimate a woman’s risk for developing breast cancer.
RiskScore is calculated for women under age 85 without a personal history of breast cancer, LCIS, hyperplasia, atypical hyperplasia, or a breast biopsy with unknown results. RiskScore is not calculated if the patient is known to carry a mutation in a breast cancer risk gene other that CHEK2, or if there are any known mutations in high-penetrance breast cancer risk genes in the patient’s family.
To learn more about RiskScore and the medical management guidelines provided for patients identified to have a remaining lifetime risk of breast cancer >20%, you may view the result insert by clicking the link below.
View RiskScore Insert
Genes selected for MyRisk satisfy these criteria:
Each gene tested with MyRisk links to one or more of 11 cancer sites:
Breast, Ovarian, Colorectal, Uterine, Skin, Pancreatic, Gastric, Prostate, Renal, Lung, and Endocrine.
MyRisk simplifies the test selection process by providing you the most comprehensive hereditary cancer panel test with clinically significant results. Be confident you are testing for the primary clinically significant genes associated with your patients’ risk.
Identifies risk of developing 11 hereditary cancers
Identifies risk of breast cancer recurrence to inform treatment strategies
Identifies BRCA1/2 mutations to inform treatment strategies
Identifies HRD status to inform treatment strategies
Identifies prostate cancer aggressiveness to inform treatment strategies
Identifies at-risk couples for a pregnancy affected by inherited conditions
Identifies risk of chromosomal conditions for expectant parents
Identifies how genes affect outcomes with certain mental health medications
2023 Myriad, the Myriad logo, MyriadPro, the MyriadPro logo, Myriad MyRisk Hereditary Cancer, the Myriad MyRisk Hereditary Cancer logo, BRACAnalysis, the BRACAnalysis logo, Prolaris, the Prolaris logo, Foresight, the Foresight logo, GeneSight, the GeneSight logo, MyChoice, MyChoice logo, Endopredict, the Endopredict logo, Prequel, the Prequel logo are either trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and other jurisdictions.